Jonathan Richard Selected Research

COVID-19

5/2024	Sustained IFN signaling is associated with delayed development of SARS-CoV-2-specific immunity.
1/2023	The Fc-effector function of COVID-19 convalescent plasma contributes to SARS-CoV-2 treatment efficacy in mice.
7/2022	VE607 stabilizes SARS-CoV-2 Spike in the "RBD-up" conformation and inhibits viral entry.
2/2022	VE607 Stabilizes SARS-CoV-2 Spike In the "RBD-up" Conformation and Inhibits Viral Entry.
1/2022	A Fc-enhanced NTD-binding non-neutralizing antibody delays virus spread and synergizes with a nAb to protect mice from lethal SARS-CoV-2 infection.
12/2021	Evaluating Humoral Immunity against SARS-CoV-2: Validation of a Plaque-Reduction Neutralization Test and a Multilaboratory Comparison of Conventional and Surrogate Neutralization Assays.
11/2021	Integrated immunovirological profiling validates plasma SARS-CoV-2 RNA as an early predictor of COVID-19 mortality.
6/2021	Live Imaging of SARS-CoV-2 Infection in Mice Reveals Neutralizing Antibodies Require Fc Function for Optimal Efficacy.
1/2021	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.
1/2021	Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Jonathan Richard Research Topics

Disease

18	Infections 02/2024 - 09/2013
13	COVID-19 05/2024 - 10/2020
3	Inflammation (Inflammations) 02/2024 - 08/2023
3	Disease Progression 12/2023 - 10/2016
3	HIV Infections (HIV Infection) 04/2020 - 01/2018
2	Viremia 11/2023 - 08/2023
2	Premature Aging 11/2023 - 08/2023
2	Cardiovascular Diseases (Cardiovascular Disease) 11/2023 - 08/2023
2	Atherosclerotic Plaque (Atheroma) 11/2023 - 08/2023
2	Coronary Artery Disease (Coronary Atherosclerosis) 11/2023 - 08/2023
2	Convalescence 01/2021 - 01/2021
2	Coinfection 01/2021 - 01/2021
2	Fibrosis (Cirrhosis) 10/2018 - 01/2018
1	Systemic Lupus Erythematosus (Libman-Sacks Disease) 12/2023
1	Virus Diseases (Viral Diseases) 12/2019
1	Liver Cirrhosis (Hepatic Cirrhosis) 10/2018
1	Chronic Renal Insufficiency 01/2018
1	Ureteral Obstruction 01/2018

Drug/Important Bio-Agent (IBA)

7	Neutralizing AntibodiesIBA 01/2022 - 01/2015
6	AntibodiesIBA 11/2023 - 12/2019
6	VaccinesIBA 01/2022 - 01/2015
4	Glycoproteins (Glycoprotein)IBA 03/2024 - 02/2022
2	InterferonsIBA 05/2024 - 12/2023
2	CytokinesIBA 11/2023 - 08/2023
2	piperidineIBA 03/2023 - 01/2023
2	1- (3- (2- hydroxyl- 3- piperidin- 1- yl- propoxy)- phenoxy)- 3- piperidin- 1- ylpropan- 2- olIBA 07/2022 - 02/2022
2	DNA (Deoxyribonucleic Acid)IBA 04/2020 - 01/2020
2	setogepramIBA 10/2018 - 01/2018
2	LigandsIBA 01/2018 - 10/2016
1	Interleukin-6 (Interleukin 6)IBA 03/2024
1	Metformin (Glucophage)FDA LinkGeneric 02/2024
1	B-Cell Activating FactorIBA 12/2023
1	Immunoglobulin G (IgG)IBA 12/2023
1	Immunoglobulins (Immunoglobulin)IBA 01/2023
1	Antiviral Agents (Antivirals)IBA 01/2023
1	indolineIBA 01/2023
1	mRNA VaccinesIBA 10/2022
1	BNM-III-170IBA 01/2022
1	RNA (Ribonucleic Acid)IBA 11/2021
1	EpitopesIBA 10/2021
1	Immunoglobulin A (IgA)IBA 01/2021
1	Immunoglobulin M (IgM)IBA 01/2021
1	Hepatitis A Virus Cellular Receptor 2IBA 01/2020
1	HLA-C Antigens (HLA-C)IBA 01/2020
1	Phosphotransferases (Kinase)IBA 10/2018
1	Carbon Tetrachloride (Tetrachloromethane)IBA 10/2018
1	TOR Serine-Threonine KinasesIBA 10/2018
1	Adenosine Triphosphate (ATP)IBA 10/2018
1	AMP-Activated Protein KinasesIBA 10/2018
1	Adenine FDA LinkGeneric 01/2018
1	vpr Gene ProductsIBA 09/2013

Therapy/Procedure

8	Therapeutics 11/2023 - 01/2018
3	Art Therapy 02/2024 - 01/2020
2	Immunotherapy 07/2022 - 02/2022
1	Ligation 10/2018